Cite
HARVARD Citation
Koguchi, Y. et al. (n.d.). 760 Trough levels of ipilimumab in serum as a potential predictive biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab. Journal for immunotherapy of cancer. p. A808. [Online].